A phase II trial of high‐dose intravenous interferon alpha‐2 in advanced colorectal cancer
Twenty‐one patients with metastatic colorectal cancer were treated with high‐dose intravenous interferon alpha‐2 (30–50 × 106 units/m2) administered daily for 5 consecutive days. Courses of therapy were repeated every 2 to 3 weeks. No tumor responses were seen among 15 evaluable patients. In two sub...
Saved in:
| Published in | Cancer Vol. 54; no. 10; pp. 2257 - 2261 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article Conference Proceeding |
| Language | English |
| Published |
New York
Wiley Subscription Services, Inc., A Wiley Company
15.11.1984
Wiley-Liss |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0008-543X 1097-0142 |
| DOI | 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C |
Cover
Loading…
| Abstract | Twenty‐one patients with metastatic colorectal cancer were treated with high‐dose intravenous interferon alpha‐2 (30–50 × 106 units/m2) administered daily for 5 consecutive days. Courses of therapy were repeated every 2 to 3 weeks. No tumor responses were seen among 15 evaluable patients. In two subjects, disease remained stable for 3 and 7 months, respectively. Toxicity was substantial and a de‐escalation of dose was frequently required. Fevers, gastrointestinal symptoms, fatigue, leukopenia, and elevated serum transaminases were common. High‐dose interferon was found to be ineffective in the treatment of metastatic colorectal cancer. A daily dose of 50 × 106 units/m2 was greater than the maximum tolerated dose in this group of patients. |
|---|---|
| AbstractList | Twenty-one patients with metastatic colorectal cancer were treated with high-dose intravenous interferon alpha-2 (30-50 X 10(6) units/m2) administered daily for 5 consecutive days. Courses of therapy were repeated every 2 to 3 weeks. No tumor responses were seen among 15 evaluable patients. In two subjects, disease remained stable for 3 and 7 months, respectively. Toxicity was substantial and a de-escalation of dose was frequently required. Fevers, gastrointestinal symptoms, fatigue, leukopenia, and elevated serum transaminases were common. High-dose interferon was found to be ineffective in the treatment of metastatic colorectal cancer. A daily dose of 50 X 10(6) units/m2 was greater than the maximum tolerated dose in this group of patients. Twenty-one patients with metastatic colorectal cancer were treated with high-dose intravenous interferon alpha-2 (30-50 X 10(6) units/m2) administered daily for 5 consecutive days. Courses of therapy were repeated every 2 to 3 weeks. No tumor responses were seen among 15 evaluable patients. In two subjects, disease remained stable for 3 and 7 months, respectively. Toxicity was substantial and a de-escalation of dose was frequently required. Fevers, gastrointestinal symptoms, fatigue, leukopenia, and elevated serum transaminases were common. High-dose interferon was found to be ineffective in the treatment of metastatic colorectal cancer. A daily dose of 50 X 10(6) units/m2 was greater than the maximum tolerated dose in this group of patients.Twenty-one patients with metastatic colorectal cancer were treated with high-dose intravenous interferon alpha-2 (30-50 X 10(6) units/m2) administered daily for 5 consecutive days. Courses of therapy were repeated every 2 to 3 weeks. No tumor responses were seen among 15 evaluable patients. In two subjects, disease remained stable for 3 and 7 months, respectively. Toxicity was substantial and a de-escalation of dose was frequently required. Fevers, gastrointestinal symptoms, fatigue, leukopenia, and elevated serum transaminases were common. High-dose interferon was found to be ineffective in the treatment of metastatic colorectal cancer. A daily dose of 50 X 10(6) units/m2 was greater than the maximum tolerated dose in this group of patients. Twenty‐one patients with metastatic colorectal cancer were treated with high‐dose intravenous interferon alpha‐2 (30–50 × 106 units/m2) administered daily for 5 consecutive days. Courses of therapy were repeated every 2 to 3 weeks. No tumor responses were seen among 15 evaluable patients. In two subjects, disease remained stable for 3 and 7 months, respectively. Toxicity was substantial and a de‐escalation of dose was frequently required. Fevers, gastrointestinal symptoms, fatigue, leukopenia, and elevated serum transaminases were common. High‐dose interferon was found to be ineffective in the treatment of metastatic colorectal cancer. A daily dose of 50 × 106 units/m2 was greater than the maximum tolerated dose in this group of patients. |
| Author | Rudnick, Seth Schein, Philip S. Ahlgren, James D. Rothman, John Galicky, F. Peter Silgals, Robert M. Neefe, John R. |
| Author_xml | – sequence: 1 givenname: Robert M. surname: Silgals fullname: Silgals, Robert M. – sequence: 2 givenname: James D. surname: Ahlgren fullname: Ahlgren, James D. – sequence: 3 givenname: John R. surname: Neefe fullname: Neefe, John R. – sequence: 4 givenname: John surname: Rothman fullname: Rothman, John – sequence: 5 givenname: Seth surname: Rudnick fullname: Rudnick, Seth – sequence: 6 givenname: F. Peter surname: Galicky fullname: Galicky, F. Peter – sequence: 7 givenname: Philip S. surname: Schein fullname: Schein, Philip S. |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9176596$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/6488145$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVkd-KEzEUxoOsrN3VRxDmQkQvpp78n6kilFndLSxbEAUvxJDmz3ZkOqlJu7J3PoLP6JOY2daCXgheJTnfd76T5HeCjvrQO4TOMIwxAHmBoZYlYEae4bpiGGP-nLMJhleEcDmZTGdnZXPVvCMVAc4wUPKajmHczF-SsrmHRof2IzQCgKrkjH58gE5S-pKPknB6jI4FqyrM-Ah9nhbrpU6umM2KTWx1VwRfLNvr5c_vP2zI9bbfRH3j-rBNw95F72LoC93ltuwhuVhoe6N742xhQheiM5scY4ZKfIjue90l92i_nqIPb9-8by7Ky_n5rJleloYDJqVh4AwVlnEQhkvKQRpPJGWVFtZ6zAUYvqCGYCcWzoDnTGBPrbByYXQt6Cl6ustdx_B169JGrdpkXNfp3uWbqwoTWQvg2fh4b9wuVs6qdWxXOt6q_Ydk_cle18nozsf8jDYdbDWWgt_N-7SzmRhSis4fHBjUQFENGNSAQf2mqDgb1IGiUpmi-pOiogpUM1dENTn-ehf_re3c7X9m_zP6L4X-ArAEsoY |
| CODEN | CANCAR |
| Cites_doi | 10.1200/JCO.1983.1.2.135 10.7326/0003-4819-93-3-399 10.1002/1097-0142(19820815)50:4<646::AID-CNCR2820500405>3.0.CO;2-0 10.1002/1097-0142(197508)36:2+<675::AID-CNCR2820360810>3.0.CO;2-A 10.1002/1097-0142(19820415)49:8<1555::AID-CNCR2820490807>3.0.CO;2-C 10.1038/277221a0 10.1200/JCO.1983.1.3.217 10.7326/0003-4819-96-1-80 10.1016/S0140-6736(79)90770-0 10.1182/blood.V58.4.712.712 |
| ContentType | Journal Article Conference Proceeding |
| Copyright | Copyright © 1984 American Cancer Society 1985 INIST-CNRS |
| Copyright_xml | – notice: Copyright © 1984 American Cancer Society – notice: 1985 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-0142 |
| EndPage | 2261 |
| ExternalDocumentID | 6488145 9176596 10_1002_1097_0142_19841115_54_10_2257__AID_CNCR2820541032_3_0_CO_2_C CNCR2820541032 |
| Genre | article Journal Article |
| GroupedDBID | --- -~X .GA .GJ 05W 0R~ 1CY 1L6 1OC 24P 29B 33P 3SF 3WU 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52T 52U 52V 52W 52X 53G 5GY 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 85S 8UM AAESR AAHHS AAONW AARRQ AAWTL ABCQN ABEML ABHFT ABIVO ABJNI ABLJU ABOCM ABPPZ ACGFO ACGFS ACNCT ACPRK ACSCC ACXQS ADBBV ADKYN ADOZA ADZMN ADZOD AENEX AEUQT AFBPY AFFPM AFRAH AGNAY AI. AIAGR ALAGY ALMA_UNASSIGNED_HOLDINGS AMBMR ATUGU AZBYB BAFTC BAWUL BY8 C45 CS3 D-6 D-7 D-E D-F DIK DR2 DRFUL E3Z EBS EJD F04 F5P FD6 GNP GODZA GX1 H.X HBH HHY HHZ HZ~ IH2 IX1 J0M J5H JPC KQQ KZ1 L7B LATKE LC2 LC3 LITHE LOXES LSO LUTES LW6 MK4 MRFUL MRMAN MSFUL MSSTM N04 N05 N9A NEJ NF~ NNB O66 O9- OHT OIG OK1 OVD P2P P2W P2X P2Z P4B Q.N QRW RWI RX1 SJN SUPJJ TEORI UDS UHB V8K V9Y VH1 W8V W99 WBKPD WH7 WIH WIJ WIK WIN WJL WVDHM WXI XV2 Z0Y ZGI ZXP ~WT AAYXX ACCZN AEYWJ CITATION .3N .Y3 10A 31~ 3O- 4.4 52S 5VS 8-3 8-4 8-5 930 A01 A03 AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAQOH AAXRX AAYCA AAZKR ABCUV ABIJN ABPVW ABQWH ABXGK ACAHQ ACFBH ACGOF ACMXC ACPOU ACXBN ADBTR ADEOM ADIZJ ADMGS ADXAS AEFGJ AEIGN AEIMD AEUYR AFFNX AFGKR AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AIACR AIDQK AIDYY AITYG AIURR ALUQN ALVPJ AMYDB AZVAB BFHJK BHBCM BMXJE BROTX BRXPI C1A DCZOG DPXWK DRMAN DRSTM EMOBN EX3 F00 F01 FUBAC G-S G.N HF~ HGLYW H~9 IQODW KBYEO LAW LH4 LMP LP6 LP7 LYRES MEWTI MRSTM MSMAN MXFUL MXMAN MXSTM N4W P4D Q11 QB0 R.K ROL RSU RYL V2E WHG WHWMO WOHZO WQJ WXSBR XG1 XPP Y6R YQJ ZZTAW ~IA CGR CUY CVF ECM EIF NPM VXZ 7X8 |
| ID | FETCH-LOGICAL-c5012-c40ec36d4506c573507cf27348a6ddf1560c5b3c21e6bec0f5461f3d6d7bca963 |
| ISSN | 0008-543X |
| IngestDate | Thu Sep 04 21:08:59 EDT 2025 Wed Feb 19 02:33:27 EST 2025 Mon Jul 21 09:13:18 EDT 2025 Tue Jul 01 01:55:31 EDT 2025 Wed Jan 22 16:19:47 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | Antineoplastic agent Human Intravenous administration Alpha interferon Treatment Immunotherapy Phase II trial Rectum Digestive diseases Intestinal disease Advanced stage Tumor Colon High dose |
| Language | English |
| License | http://doi.wiley.com/10.1002/tdm_license_1.1 CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c5012-c40ec36d4506c573507cf27348a6ddf1560c5b3c21e6bec0f5461f3d6d7bca963 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2819841115%2954%3A10%3C2257%3A%3AAID-CNCR2820541032%3E3.0.CO%3B2-C |
| PMID | 6488145 |
| PQID | 81279605 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_81279605 pubmed_primary_6488145 pascalfrancis_primary_9176596 crossref_primary_10_1002_1097_0142_19841115_54_10_2257__AID_CNCR2820541032_3_0_CO_2_C wiley_primary_10_1002_1097_0142_19841115_54_10_2257_AID_CNCR2820541032_3_0_CO_2_C_CNCR2820541032 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 1900 |
| PublicationDate | 15 November 1984 |
| PublicationDateYYYYMMDD | 1984-11-15 |
| PublicationDate_xml | – month: 11 year: 1984 text: 15 November 1984 day: 15 |
| PublicationDecade | 1980 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: New York, NY – name: United States |
| PublicationTitle | Cancer |
| PublicationTitleAlternate | Cancer |
| PublicationYear | 1984 |
| Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley-Liss |
| Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley-Liss |
| References | 1982; 23 1981; 58 1975; 36 1982; 49 1980; 93 1979; 1 1979; 277 1983; 2 1982; 50 1983; 1 1982; 96 1983; 67 Davis (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB1) 1982; 50 Smith (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB5) 1982; 23 Weltz (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB3) 1983; 1 Herberman (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB13) 1979; 277 Moertel (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB2) 1975; 36 Engstrom (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB4) 1982; 49 Gutterman (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB6) 1980; 93 Stiehm (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB12) 1982; 96 Louie (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB7) 1981; 58 Figlin (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB10) 1983; 67 Mellstedt (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB8) 1979; 1 Koren (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB14) Neefe (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB9) Chaplinski (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB11) 1983; 2 Salmon (10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB15) 1983; 1 |
| References_xml | – volume: 1 start-page: 217 year: 1983 end-page: 225 article-title: Effects of cloned human leukocyte interferons in the human tumor stem cell assay publication-title: J Clin Oncol – volume: 2 start-page: 130 year: 1983 article-title: Phase II trial of interferon (IFN) in metastatic colon cancer. (Abstr) publication-title: ASCO – volume: 93 start-page: 399 year: 1980 end-page: 406 article-title: Leukocyte interferon‐induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma publication-title: Ann Intern Med – volume: 67 start-page: 493 year: 1983 end-page: 494 article-title: Phase II trial of alpha (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectum publication-title: Cancer Treat Rep – volume: 36 start-page: 675 year: 1975 end-page: 685 article-title: Clinical management of advanced gastrointestinal cancer publication-title: Cancer – volume: 1 start-page: 245 year: 1979 end-page: 247 article-title: Interferon therapy in myelomatosis publication-title: Lancet – volume: 96 start-page: 80 year: 1982 end-page: 93 article-title: Interferon: Immunobiology and clinical significance publication-title: Ann Intern Med – volume: 50 start-page: 2638 year: 1982 end-page: 2646 article-title: Chemotherapy of large bowel cancer publication-title: Cancer – volume: 277 start-page: 221 year: 1979 end-page: 223 article-title: Augmentation by interferon of human natural and antibody‐dependent cell‐mediated cytotoxicity publication-title: Nature – volume: 49 start-page: 1555 year: 1982 end-page: 1560 article-title: Combination chemotherapy of advanced colorectal cancer utilizing 5‐fluorouracil, semustine, decarbazine, vincristine, and hydroxyurea: A Phase III trial by the Eastern Oncology Group (EST:4275) publication-title: Cancer – volume: 58 start-page: 712 year: 1981 end-page: 718 article-title: Follow‐up observations on the effect of human leukocyte interferon in non‐Hodgkin's lymphoma publication-title: Blood – volume: 23 start-page: 149 year: 1982 article-title: Phase II study of MOF‐Strep (Methyl‐CCNU, vincristine, 5‐fluorouracil, streptozotocin) in advanced measurable colorectal cancer. A GITSG trial (Abstr) publication-title: Proc Am Assoc Cancer Res – volume: 1 start-page: 135 year: 1983 end-page: 137 article-title: Methyl‐CCNU, 5‐fluorouracil, vincristine, and streptozotocin (MOF‐Strep) in metastatic colorectal cancer publication-title: J Clin Oncol – volume: 1 start-page: 135 year: 1983 ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB3 publication-title: J Clin Oncol doi: 10.1200/JCO.1983.1.2.135 – ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB9 – volume: 67 start-page: 493 year: 1983 ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB10 publication-title: Cancer Treat Rep – ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB14 – volume: 93 start-page: 399 year: 1980 ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB6 publication-title: Ann Intern Med doi: 10.7326/0003-4819-93-3-399 – volume: 23 start-page: 149 year: 1982 ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB5 publication-title: Proc Am Assoc Cancer Res – volume: 50 start-page: 2638 year: 1982 ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB1 publication-title: Cancer doi: 10.1002/1097-0142(19820815)50:4<646::AID-CNCR2820500405>3.0.CO;2-0 – volume: 36 start-page: 675 year: 1975 ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB2 publication-title: Cancer doi: 10.1002/1097-0142(197508)36:2+<675::AID-CNCR2820360810>3.0.CO;2-A – volume: 49 start-page: 1555 year: 1982 ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB4 publication-title: Cancer doi: 10.1002/1097-0142(19820415)49:8<1555::AID-CNCR2820490807>3.0.CO;2-C – volume: 277 start-page: 221 year: 1979 ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB13 publication-title: Nature doi: 10.1038/277221a0 – volume: 1 start-page: 217 year: 1983 ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB15 publication-title: J Clin Oncol doi: 10.1200/JCO.1983.1.3.217 – volume: 2 start-page: 130 year: 1983 ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB11 publication-title: ASCO – volume: 96 start-page: 80 year: 1982 ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB12 publication-title: Ann Intern Med doi: 10.7326/0003-4819-96-1-80 – volume: 1 start-page: 245 year: 1979 ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB8 publication-title: Lancet doi: 10.1016/S0140-6736(79)90770-0 – volume: 58 start-page: 712 year: 1981 ident: 10.1002/1097-0142(19841115)54:10<2257::AID-CNCR2820541032>3.0.CO;2-C-BIB7 publication-title: Blood doi: 10.1182/blood.V58.4.712.712 |
| SSID | ssj0007253 |
| Score | 1.3995172 |
| Snippet | Twenty‐one patients with metastatic colorectal cancer were treated with high‐dose intravenous interferon alpha‐2 (30–50 × 106 units/m2) administered daily for... Twenty-one patients with metastatic colorectal cancer were treated with high-dose intravenous interferon alpha-2 (30-50 X 10(6) units/m2) administered daily... |
| SourceID | proquest pubmed pascalfrancis crossref wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 2257 |
| SubjectTerms | Adult Aged Biological and medical sciences Chemical and Drug Induced Liver Injury Colonic Neoplasms - therapy Dose-Response Relationship, Drug Drug Evaluation Fatigue - chemically induced Female Fever - chemically induced Humans Immunomodulators Infusions, Parenteral Interferon Type I - administration & dosage Interferon Type I - adverse effects Interferon Type I - therapeutic use Leukopenia - chemically induced Liver Diseases - enzymology Male Medical sciences Middle Aged Nausea - chemically induced Neoplasm Metastasis Pharmacology. Drug treatments Rectal Neoplasms - therapy |
| Title | A phase II trial of high‐dose intravenous interferon alpha‐2 in advanced colorectal cancer |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2F1097-0142%2819841115%2954%3A10%3C2257%3A%3AAID-CNCR2820541032%3E3.0.CO%3B2-C https://www.ncbi.nlm.nih.gov/pubmed/6488145 https://www.proquest.com/docview/81279605 |
| Volume | 54 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF6FIlVIPHC0IkBhH4gEijbY613HCYcUXLdxlQOFRIr6ssSX6Esa5eCBP8NfZcbrI2kjUJEiK1nHzsTfeA7vzLeEvHEcmUSmCBl4E8EEfGAQx5ksjIXJISIQzgx7h_sDuzsRF1M5rVR-b1UtbdZBI_y1t6_kf1CFMcAVu2TvgGxxUhiA94AvbAFh2N7GeK-rcRG05TbunfriB3imuu_X9YocGA1CBs4irEy_wme5PzUvKzJFLJN4ifXI2HHLOD78KIoCkM4azSESiGz9yubTN793npX8jRrl09ROt3c-8tKqgYtGWUg88LwzLxssZ5WG426_MyinpSLdiOcIbMDTnZeldWO9q9Vqx7w6TIp0gd_CvGqO6FyNjG1jyTU3deZ4IRA09xp1TRKLU-UMEjqOBFYgDxhpWcNZypR0oma5eDp4D6-Of8rcgTuCdBIiUqQMrFme1TAa7rBmfeHMLZ1fPuF_wycWlYqQzdqyZd8j97kFwRR2k0_LGqImz2hOs_99SE4zgd8X4r7NhX0nRds0PqKY7fZtET9rAT-AeDsx0sPFbAW3a6LXWdmXCO3mVWlgNH5EjsqWUfq10NDHpBLPn5DDfla58ZRcdmiql9T3aaqX9DqhhV7SLb2kpV7STC9hiOZ6SUu9pFovj8jkzBu7XZat68FCCfEQC4URh5YdCWnYoWxakJKESUqzNLOjKMHe_lAGVsjN2AYTYyRS2GZiRXbUDMIZeIxjcjC_nsfPCIWjOXzBgSgcQmM-c0QsWqKZBJG0Ax47VTLJr6RaaPoWpYm6eVZ7AQipHCElBe5FhJQChNQuQspShnKHiiu3Sk52YClOnulLlbzOYVJgr3ESbjaP4RoqCKibLduQVXKs0SsOtcGXmgJ2fE_RvKO8fxX3xp7n_5D-BXlQ3vEvycF6uYlPIPZeB69S_f8DKey75Q |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=proceeding&rft.title=Cancer&rft.atitle=A+phase+II+trial+of+high-dose+intravenous+interferon+alpha-2+in+advanced+colorectal+cancer&rft.au=SILGALS%2C+R.+M&rft.au=AHLGREN%2C+J.+D&rft.au=NEEFE%2C+J.+R&rft.au=ROTHMAN%2C+J&rft.date=1984-11-15&rft.pub=Wiley-Liss&rft.issn=0008-543X&rft.volume=54&rft.issue=10&rft.spage=2257&rft.epage=2261&rft_id=info:doi/10.1002%2F1097-0142%2819841115%2954%3A10%3C2257%3A%3AAID-CNCR2820541032%3E3.0.CO%3B2-C&rft.externalDBID=n%2Fa&rft.externalDocID=9176596 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |